The European Medicines Agency (EMA) has granted approval for the first respiratory syncytial virus (RSV) vaccine for adults aged 60 years and older. The vaccine, developed by GSK and marketed as Arexvy, is designed to help protect older adults from RSV-related lower respiratory tract disease, which can lead to serious complications in this age group.

Clinical trials demonstrated that Arexvy significantly reduced the risk of RSV-associated illness in older adults, with a favorable safety profile. The EMA's decision follows a comprehensive review of the vaccine's efficacy and safety data, paving the way for its availability across European Union member states.

This approval marks a significant step in addressing the burden of RSV among older populations in Europe. Healthcare professionals are encouraged to stay informed about vaccination recommendations and implementation timelines in their respective countries. For more details, visit the EMA announcement.